Clinical TrialsEnrollment for the pivotal phase 3 trials of OCS-01 in DME is complete, keeping the program on track for a key topline data readout.
Financial StabilityWith cash runway extended into early 2028, Oculis is well-funded through key data catalysts.
Product DevelopmentOCS-01 aims to be the first non-invasive therapy for DME, potentially expanding the market to patients who typically go untreated.